Summit Therapeutics (SMMT) Total Liabilities (2018 - 2025)
Summit Therapeutics (SMMT) has disclosed Total Liabilities for 7 consecutive years, with $69.5 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Total Liabilities rose 6.98% year-over-year to $69.5 million, compared with a TTM value of $69.5 million through Sep 2025, up 6.98%, and an annual FY2024 reading of $46.8 million, down 62.63% over the prior year.
- Total Liabilities was $69.5 million for Q3 2025 at Summit Therapeutics, up from $64.6 million in the prior quarter.
- Across five years, Total Liabilities topped out at $537.5 million in Q4 2022 and bottomed at $22.1 million in Q3 2022.
- Average Total Liabilities over 5 years is $98.1 million, with a median of $64.9 million recorded in 2024.
- The sharpest move saw Total Liabilities skyrocketed 1686.35% in 2022, then crashed 76.7% in 2023.
- Year by year, Total Liabilities stood at $30.1 million in 2021, then surged by 1686.35% to $537.5 million in 2022, then plummeted by 76.7% to $125.3 million in 2023, then tumbled by 62.63% to $46.8 million in 2024, then skyrocketed by 48.39% to $69.5 million in 2025.
- Business Quant data shows Total Liabilities for SMMT at $69.5 million in Q3 2025, $64.6 million in Q2 2025, and $39.5 million in Q1 2025.